publication date: Jul. 2, 2015

Lowy’s First Director’s Report to Advisory Panel 

 

 

 

The following is a transcript of NCI Acting Director Douglas Lowy’s remarks to the joint meeting of the National Cancer Advisory Board and the NCI Board of Scientific Advisors, June 24:

I’m coming to the close of my third month as acting director, and I’d like to give you a status report. It has been really interesting and exciting for me and I can’t thank all of you enough for your incredible support—both my colleagues in NCI, and so many of you extramural colleagues.

So let me first talk about how we are planning to continue the majority of the programs that have been ongoing—and one program that I would like to highlight and come back to, actually, a little later in the discussion, is the Outstanding Investigator Award, and we are going to be announcing the first recipients in the next few weeks. But just to remind everyone, the purpose of the Outstanding Investigator Award is to provide long-term support to experienced investigators with outstanding records in cancer research, and who propose to conduct exceptional research.

It’s to allow them the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques.

And I want to divide the next few discussions into different aspects of precision medicine. You will hear later this morning from Jim Doroshow, Lou Staudt and Warren Kibbe about the Precision Medicine Initiative in oncology, and it certainly has been a very important focus for us, … Continue reading 41-26 Lowy’s First Director’s Report to Advisory Panel

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2019 The Cancer Letter Inc.